Anti-TNF-alpha therapy for orofacial granulomatosis: proceed with caution.
Gaya
D R
DR
Aitken
S
S
Fennell
J
J
Satsangi
J
J
Shand
A G
AG
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002481:Cellulitis / Q000139:chemically induced; D003875:Drug Eruptions / Q000209:etiology; D004487:Edema / Q000139:chemically induced; D005157:Facial Pain / Q000139:chemically induced*; D005260:Female; D005334:Fever / Q000139:chemically induced; D051261:Granulomatosis, Orofacial / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab